Compare CTRN & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTRN | IVVD |
|---|---|---|
| Founded | 1946 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.5M | 437.1M |
| IPO Year | 2005 | 2021 |
| Metric | CTRN | IVVD |
|---|---|---|
| Price | $37.83 | $1.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $52.00 | $8.75 |
| AVG Volume (30 Days) | 76.0K | ★ 2.2M |
| Earning Date | 06-02-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 112.14 | 79.02 |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $819,962,000.00 | $53,426,000.00 |
| Revenue This Year | $8.81 | $61.57 |
| Revenue Next Year | $8.35 | $41.42 |
| P/E Ratio | $64.11 | ★ N/A |
| Revenue Growth | 8.88 | ★ 110.47 |
| 52 Week Low | $25.03 | $0.49 |
| 52 Week High | $56.78 | $3.07 |
| Indicator | CTRN | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 28.90 | 30.90 |
| Support Level | $34.43 | $0.49 |
| Resistance Level | $38.39 | $1.14 |
| Average True Range (ATR) | 3.04 | 0.12 |
| MACD | -1.00 | -0.04 |
| Stochastic Oscillator | 0.21 | 0.00 |
Citi Trends Inc is a differentiated off-price value retailer known for trendy fashions, great brands and amazing prices. It is the off-price retailer specifically focused on Black customers, delivering the styles, brands, and trends at amazing prices that resonate with its primary and secondary customers. Its product offering is Women's, Men's and Children's apparel, family footwear, accessories and products for the home, with a three-tiered mix of product. At the opening price point, the company offers value-focused basics for its budget-conscious customers.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.